ClinicalTrials.gg
RecruitingNCT07079631Updated Jul 1, 2026

A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

A Phase 1/2 interventional study of BNT314 and Pumitamig in Metastatic Colorectal Cancer, sponsored by BioNTech SE. Recruiting at 14 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-01.

Sponsored by BioNTech SE · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
482
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 2,339 studies in Colorectal Neoplasms with a site in United States — 418 open to participants now, 630 under way, 30 of them phase 3. Colorectal Neoplasms · United States.

Planned enrollment
303rd of 1,932
482 · median 64
Started
2025
with 142 others
Phase 1/2
266 of 2,339
68 open now
Primary completion
2030-12
later than 598 of 628 live
Registered
2,171st of 2,339
by date

Among the 2,339 studies in Colorectal Neoplasms with a site in United States, this one is the 303rd largest by planned enrollment of the 1,932 interventional ones that give a count, is one of 143 that started in 2025, is one of 266 in phase 1/2, reaches primary completion later than 598 of the 628 other live ones, and was the 2,171st registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

418 of the 2,339 studies in Colorectal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

413 more — sign in →

All 418 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,181 Colorectal Neoplasms studies recruiting now, 764 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,339 studies in Colorectal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This randomized, multi-site, three-part study will test a new treatment called BNT314, which is designed to help the body's own defense to fight cancer in combination with another new treatment (pumitamig, which is a cancer immunotherapy drug also known as BNT327 and PM8002) and chemotherapy in participants with metastatic colorectal cancer (mCRC).

Read the detailed description

Participants with microsatellite stable or mismatch repair proficient (MSS/pMMR) mCRC with progressive disease to the metastatic first line (1L) setting (Parts B and C) and beyond (Part A) as well as treatment-naïve (for Part B) are eligible to participate in the study.

The main study goals are as follows:

  • Part A (Phase 1, safety run-in, dose escalation): To see if BNT314 in combination with pumitamig can be given safely, without causing severe side effects in participants.
  • Part B (Phase 1, dose optimization): To see if BNT314 in combination with pumitamig and standard of care (SoC) chemotherapy is safe for participants and to find out the right dose of BNT314 that can be used in Part C.
  • Part C (Phase 2, randomization against SoC): To see how well treatment works when BNT314 and pumitamig are given in combination with the usual SoC chemotherapy treatment.

In all three parts, the study will also look whether BNT314 can shrink tumors or slow down their growth when used with pumitamig and chemotherapy.

The study consists of a period to assess eligibility, a treatment period, a safety follow-up period, and a long-term survival follow-up period.

The sponsor plans to proactively assess participant safety on a regular basis for the duration of the study according to a predefined internal review committee. In addition, an independent data monitoring committee will be developed to provide medical oversight over Part C of the study.

Participants in the study will continue to receive treatment until their disease worsens, they can no longer tolerate the treatment, the participant chooses to leave the study, or the study ends. They are expected to be on treatment for about of 6-10 months on average. Participants may stop treatment early if their disease worsens or side effects occur but can continue longer if the disease stays controlled and the therapy is well-tolerated. After that, they will be monitored for their survival and any potential long-term side effects even after they stop participating in the study. Participants will be randomized to the treatment groups in Part B and Part C, which means participants will be assigned by equal chance to a treatment group.

03

Conditions studied

  • Metastatic Colorectal Cancer

Keywords

  • Microsatellite stable or mismatch repair proficient (MSS/pMMR) tumors
  • Immune checkpoint inhibitor
  • Programmed death-ligand 1 (PD-L1)
  • Vascular endothelial growth factor-A (VEGF-A)
  • Bispecific antibody
  • Immunotherapy
  • Combination chemotherapy
  • Dose optimization
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Have unresectable confirmed adenocarcinoma of the colon or rectum.
  • Have confirmed non-microsatellite instability-high (non-MSI-H)/pMMR mCRC per Food and Drug Administration (FDA)/European Commission (EC) approved test or based on local testing.
  • Have defined by v1.1.
  • Must provide a tumor tissue sample (formalin-fixed, paraffin-embedded or tissue slides) collected before C1D1 for enrollment. A newly obtained tumor sample is preferred. If it is not feasible to obtain a recent tumor sample, participants can provide (less than 2 years prior treatment).
  • Have Performance Status of 0 or 1.
  • Have a of ≥12 weeks.
  • Have an adequate organ and bone marrow function within ≤7 days of Day 1 as defined in the protocol.
  • Have had an adequate previous treatment before randomization/enrollment as defined in the protocol.

Inclusion criteria applicable to only protocol-specific cohorts:

  • Have histologically confirmed colorectal cancer and radiographically documented disease progression after ≥2 for metastatic disease as defined in the protocol.
  • Have progressed following first-line chemotherapy as specified in the protocol.
  • Have not received prior systemic therapy for MSS/pMMR mCRC. Participants who received chemotherapy, radiotherapy, or chemoradiotherapy with curative intent for non-metastatic disease in the or adjuvant setting are eligible for the study if therapy was completed at least 6 months prior to initiation of study treatment.

Other cohort-specific inclusion criteria apply.

Key Exclusion Criteria:

  • Confirmed MSI-H/deficient mismatch repair mCRC (per FDA/CE approved test or based on local testing).
  • Prior treatment with epithelial cell-adhesion molecule or 4-1BB targeted or immunotherapy.
  • Prior treatment with or programmed death-ligand 1 (PD[L]-1)/vascular endothelial growth factor bispecific antibody.
  • Is a candidate to locoregional treatment (including surgical resection, stereotactic radiation therapy or tumor ablation) with potential to induce complete or near complete response and prolonged tumor control (sometimes described as "radical" intent), per investigator's assessment.
  • Have uncontrolled or significant cardiovascular disease as specified in the protocol.
  • Have \<50% by echocardiogram or multigated acquisition within 28 days before randomization/enrollment.
  • Have clinically uncontrolled pleural effusion, ascites or pericardial effusion requiring drainage, peritoneal shunt, or cell-free concentrated ascites reinfusion therapy within 2 weeks prior to randomization/enrollment.
  • Have clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with or anticonvulsants to control associated symptoms. Participants with treated that are no longer symptomatic and who require no treatment with corticosteroids or anticonvulsants may be included in the study if they have recovered from the acute toxic effect of radiotherapy. Participants with untreated, asymptomatic brain metastases for whom local therapy is not indicated per SoC may be eligible if neurologically stable and (if deemed necessary by the investigator). Except for brain metastases history, any participants at imminent risk for spinal cord compression or are not eligible.
  • Have unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤1 or baseline toxicities that have resolved with sequelae (e.g., tracheostomy, chronic use of feeding tube, replacement hormones) are allowed, if not associated with increased risk of complications per investigator's assessment.
  • Participants in Part B or C who fulfill one of the conditions:

    • Prior treatment with anticancer therapies (as defined in the protocol) with unusual toxicity, or
    • Known dihydropyrimidine dehydrogenase (DPD) deficiency, testing performed according to the local guidelines. If not tested, lack of DPD activity must be tested for the participants who have not received anticancer therapies (as defined in the protocol) in the prior lines of treatment; testing should be performed according to the local guidelines.
  • Have a history of another primary within 2 years, except adequately resected non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated (adjuvant hormone therapy for malignancies at low risk of relapse is allowed) or have a known additional malignancy that is progressing or requires treatment.
  • Have a history of small bowel obstruction requiring hospitalization within the past 3 months prior to the first dose of IMP.
  • Have 24-h urine protein excretion ≥1 g. If qualitative urine protein is ≤1+, a 24-h urine protein quantitative test is not required.
  • Have active disease or a history of autoimmune disease (myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, vasculitis, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, or multiple sclerosis) with a risk of exacerbation following PD-L1 inhibition or have an immune deficiency ( hematopoietic stem cell transplantation or organ transplantation). Participants with protocol-specified conditions may be eligible.
  • Have serious non-healing wounds, ulcers, or bone fractures. This includes history of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess or esophageal and gastric varices, acute gastrointestinal bleeding for which an interval of 6 months must pass before enrollment into this study. In addition, the participant must have undergone correction (or spontaneous healing) of the perforation/fistula and/or the underlying process causing the fistula/perforation.
  • Have evidence of major coagulation disorders or other significant risks of hemorrhage as specified in the protocol.

NOTE: Other protocol defined Inclusion/Exclusion criteria apply.

Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
482 participants (estimated)

Study arms

  • Experimental
    Phase 1 (Part A): BNT314 (escalating dose levels) + pumitamig

    Up to 5 dose levels of BNT314. One or two dose levels of pumitamig.

    Biological: BNT314 · Drug: Pumitamig

  • Experimental
    Phase 1 (Part B): BNT314 + pumitamig + SoC chemotherapy 1

    BNT314 (optimized dose level 1 or 2 as determined based on data from Part A) + pumitamig + SoC combination chemotherapy 1. One selected dose level of pumitamig.

    Biological: BNT314 · Drug: Pumitamig · Drug: SoC chemotherapy treatment 1

  • Experimental
    Phase 1 (Part B): BNT314 + pumitamig + SoC chemotherapy 2

    BNT314 (optimized dose level 1 or 2 as determined based on data from Part A) + pumitamig + SoC combination chemotherapy 2. One selected dose level of pumitamig.

    Biological: BNT314 · Drug: Pumitamig · Drug: SoC chemotherapy treatment 2

  • Experimental
    Phase 2 (Part C): BNT314 + pumitamig + SoC chemotherapy 1

    Recommended phase 2 dose of BNT314 + pumitamig + SoC combination chemotherapy 1. One selected dose level of pumitamig.

    Biological: BNT314 · Drug: Pumitamig · Drug: SoC chemotherapy treatment 1

  • Active comparator
    Phase 2 (Part C): Bevacizumab + SoC chemotherapy 1

    Combination of two different SoC therapies

    Drug: SoC chemotherapy treatment 1 · Drug: Bevacizumab

  • Experimental
    Phase 2 (Part C): Pumitamig + SoC chemotherapy 1

    Pumitamig + SoC combination chemotherapy 1. One selected dose level of pumitamig.

    Drug: Pumitamig · Drug: SoC chemotherapy treatment 1

Interventions

  • BiologicalBNT314

    Intravenous (IV) infusion

  • IV infusion

    Also known as: BNT327, PM8002

  • DrugSoC chemotherapy treatment 1

    IV infusion / IV bolus

  • DrugSoC chemotherapy treatment 2

    IV infusion / IV bolus / oral

  • IV infusion

06

What researchers measure

Primary outcomes

  1. Phase I - Part A: Occurrence of dose limiting toxicities (DLTs) during the DLT observation period

    Time frame: Up to 28 days after Day 1, Cycle 1

  2. Phase I - Part A: Occurrence of treatment emergent adverse events (TEAEs) and treatment related adverse events (TRAEs)

    Assessed according to Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0) including Grade ≥3, serious, fatal TEAEs by relationship.

    Time frame: From initiation of the first dose of BNT314 + pumitamig until 90 days after last dose of investigational medicinal product (IMP)

  3. Phase I - Part A: Occurrence of dose interruption or discontinuation of study treatment due to TEAEs

    Time frame: From initiation of the first dose of BNT314 + pumitamig until 90 days after last dose of IMP

  4. Phase I - Part B: Occurrence DLTs during the DLT observation period for the first five participants in each dose cohort

    Time frame: Up to 42 days after Day 1, Cycle 1

  5. Phase I - Part B: Occurrence of TEAEs and TRAEs

    Assessed according to CTCAE v5.0 including Grade ≥3, serious, fatal TEAEs by relationship.

    Time frame: From initiation of the first dose of BNT314 + pumitamig + SoC chemotherapy until 90 days after last dose of IMP

  6. Phase I - Part B: Occurrence of dose interruption or discontinuation of study treatment due to TEAEs

    Time frame: From initiation of the first dose of BNT314 + pumitamig + SoC chemotherapy until 90 days after last dose of IMP

  7. Phase I - Part B: Objective response rate (ORR)

    Defined as the percentage of participants in whom a complete response (CR) or confirmed partial response (PR) (assessed by the blinded independent central review \[BICR\] per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST v1.1\]) is observed as best overall response.

    Time frame: From the time of initiation of the first dose of IMP to end of study, up to 57 months

  8. Phase II - Part C: Progression free survival

    Defined as the time from randomization to first documented tumor progression (progressive disease assessed by BICR per RECIST v1.1), or death from any cause, whichever occurs first.

    Time frame: From the time of initiation of the first dose of IMP to end of study, up to 57 months

Secondary outcomes

  1. Phase II - Part C: ORR

    Defined as the percentage of participants in whom a confirmed CR or PR (assessed by BICR per RECIST v1.1) is observed as best overall response.

    Time frame: From the time of initiation of the first dose of IMP to end of study, up to 57 months

  2. Phase I - Part A: ORR

    Defined as the percentage of participants in whom a confirmed CR or PR (assessed by BICR per RECIST v1.1) is observed as best overall response.

    Time frame: From the time of initiation of the first dose of IMP to end of study, up to 57 months

  3. All parts: Duration of response

    Defined as the time from first objective response (CR or PR assessed by BICR per RECIST v1.1) to first occurrence of objective tumor progression (progressive disease assessed by BICR per RECIST v1.1) or death from any cause, whichever occurs first.

    Time frame: From the time of initiation of the first dose of IMP to end of study, up to 57 months

  4. Phase I - Part A and Part B: Disease control rate

    Defined as the percentage of participants with confirmed CR or PR or stable disease (per RECIST v1.1, assessed at least 6 weeks after the first IMP dose) observed as best ORR per BICR.

    Time frame: From the time of initiation of the first dose of IMP to end of study, up to 57 months

  5. Phase I - Part A and Part B: Geometric mean of pharmacokinetic parameter maximum concentration of BNT314 and pumitamig in serum.

    Per dose level. If data permits.

    Time frame: From predose to 42 days after first dose of IMP

  6. Phase I - Part A and Part B: Geometric mean of pharmacokinetic parameter time taken to reach maximum concentration of BNT314 and pumitamig in serum.

    Per dose level. If data permits.

    Time frame: From predose to 42 days after first dose of IMP

  7. Phase I - Part A and Part B: Geometric mean of pharmacokinetic parameter half life of BNT314 and pumitamig in serum.

    Per dose level. If data permits.

    Time frame: From predose to 42 days after first dose of IMP

  8. Phase I - Part A: Geometric mean of pharmacokinetic parameter volume of distribution of BNT314 and pumitamig in serum.

    Per dose level. If data permits.

    Time frame: From predose to 42 days after first dose of IMP

  9. Phase I - Part A: Geometric mean of pharmacokinetic parameter area under the curve of BNT314 and pumitamig in serum.

    Per dose level. If data permits.

    Time frame: From predose to 42 days after first dose of IMP

  10. Phase I - Part A and Part B: Geometric mean of pharmacokinetic parameter clearance of BNT314 and pumitamig in serum.

    Per dose level. If data permits.

    Time frame: From predose to 42 days after first dose of IMP

  11. Phase I - Part B: Geometric mean of pharmacokinetic parameter steady state volume of distribution of BNT314 and pumitamig in serum.

    Per dose level. If data permits.

    Time frame: From predose to 42 days after first dose of IMP

  12. Phase I - Part B: Geometric mean of pharmacokinetic parameter total drug exposure across time of BNT314 and pumitamig in serum.

    Per dose level. If data permits.

    Time frame: From predose to 42 days after first dose of IMP

  13. Phase I - Part B: Geometric mean of pharmacokinetic parameter area under the concentration-time curve from pre-dose to last quantifiable time point prior to the next dose of BNT314 and pumitamig in serum.

    Per dose level. If data permits.

    Time frame: From predose to 42 days after first dose of IMP

  14. Phase I - Part A and Part B: ADA prevalence

    Percentage of participants who are ADA positive (either baseline or post-baseline). By dose level. If data permits.

    Time frame: Up to 90 days post last dose of IMP

  15. Phase I - Part A and Part B: Anti-drug antibody (ADA) incidence

    Percentage of participants having treatment-emergent ADA. By dose level. If data permits.

    Time frame: Up to 90 days post last dose of IMP

  16. Phase II - Part C: Overall survival

    Defined as the time from randomization to death from any cause

    Time frame: From the time of initiation of the first dose of IMP to end of study, up to 57 months

  17. Phase II - Part C: Occurrence of TEAEs and TRAEs

    Assessed according to CTCAE v5.0 including Grade ≥3, serious, fatal TEAEs by relationship

    Time frame: From initiation of the first dose of BNT314 + pumitamig until 90 days after last dose of IMP

  18. Phase II - Part C: Occurrence of dose interruption or discontinuation of study treatment due to TEAEs

    Time frame: From initiation of the first dose of BNT314 + pumitamig until 90 days after last dose of IMP

07

Study locations

14 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2030, 65 months after the start.

Of 158 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 82. This study's planned 65 months is above that.

Counting every sponsor, half of 260 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2025
First posted
Jul 23, 2025
StartActual
Jul 18, 2025
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2032
Last update
Jul 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07079631
Lead sponsor
BioNTech SE
Collaborators
Genmab
Responsible party
Sponsor
First posted
Jul 23, 2025
Start date
Jul 18, 2025
Primary completion
Dec 2030 (estimated)
Completion
Dec 2032 (estimated)
Last update
Jul 1, 2026

Study contacts

BioNTech clinical trials patient information
Contact
patients@biontech.de
+49 6131 9084 ext. 0
BioNTech Responsible Person
study director · BioNTech SE

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pumitamig

Start the discussion